How J&J paved the way for Compass’ coming psychedelic drug launch
Published . Updated .
In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.
Directly affected
Indirectly affected
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.
Source: BioPharma Dive
The price since 21 Sep 2026: aTYR PHARMA (ATYR) versus the S&P 500
Since the first closing price after “How J&J paved the way for Compass’ coming psychedelic drug launch,” aTYR PHARMA (ATYR) is -52.76%. The S&P 500 fund (SPY) is -0.88% over the same days, a -51.87% difference versus the market.
Disclosure records for aTYR PHARMA (ATYR) within two months of 21 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 8 days after publication, inside 30 days. The filing is listed beside the story “How J&J paved the way for Compass’ coming psychedelic drug launch.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 10 days before publication, inside 30 days. The filing is listed beside the story “How J&J paved the way for Compass’ coming psychedelic drug launch.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 49 days before publication, inside 60 days. The filing is listed beside the story “How J&J paved the way for Compass’ coming psychedelic drug launch.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “How J&J paved the way for Compass’ coming psychedelic drug launch.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “How J&J paved the way for Compass’ coming psychedelic drug launch.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 60 days before publication, inside 60 days. The filing is listed beside the story “How J&J paved the way for Compass’ coming psychedelic drug launch.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around aTYR PHARMA (ATYR)
Companies mentioned with this story
- ATYR aTYR PHARMA
For “How J&J paved the way for Compass’ coming psychedelic drug launch,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “How J&J paved the way for Compass’ coming psychedelic drug launch,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
For “How J&J paved the way for Compass’ coming psychedelic drug launch,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “How J&J paved the way for Compass’ coming psychedelic drug launch,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “How J&J paved the way for Compass’ coming psychedelic drug launch,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 21 Sep 2026 story “How J&J paved the way for Compass’ coming psychedelic drug launch.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
aTYR PHARMA (ATYR)
aTYR PHARMA (ATYR) is the company in “How J&J paved the way for Compass’ coming psychedelic drug launch,” the 21 Sep 2026 this story story.
The link for aTYR PHARMA (ATYR) is this: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
GE HealthCare Technologies (GEHC) is here too. Its reason reads: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for aTYR PHARMA (ATYR)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17. GEHC traded between 63.33 and 71.29 across 20 sessions. The latest close on file is 69.76.
How strong the case is around aTYR PHARMA (ATYR)
46 out of 100
“How J&J paved the way for Compass’ coming psychedelic drug launch” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.